Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Phase 3 LATIFY Study - Ceralasertib + Durvalumab vs. Docetaxel in Patients With Locally Advanced or Metastatic NSCLC That Progressed on or After Anti-PD-(L)1 & Platinum-Based Therapy"
By
Insights from 2023 ASCO® Annual Meeting
FEATURING
Benjamin Besse
By
Insights from 2023 ASCO® Annual Meeting
FEATURING
Benjamin Besse
Login to view comments.
Click here to Login